CONTEXT: Studies of long-term outcomes of subclinical hypothyroidism have assessed only baseline thyroid function, despite natural transitions to euthyroidism and overt hypothyroidism over time. OBJECTIVE: We provide estimates of persistence, resolution, and progression of subclinical hypothyroidism over 4 yr, stratified by baseline TSH, anti-thyroid peroxidase antibody (TPOAb) status, age, and sex. DESIGN, SETTING, AND PARTICIPANTS: Participants were 3996 U.S. individuals at least 65 yr old enrolled in the Cardiovascular Health Study. Subclinical hypothyroidism was detected at baseline in 459 individuals not taking thyroid medication. MAIN OUTCOME MEASURE: Thyroid function was evaluated at 2 and 4 yr and initiation of thyroid medication annually. Results were stratified by baseline TSH, TPOAb status, age, and sex. RESULTS: Persistence of subclinical hypothyroidism was 56% at 2 and 4 yr. At 2 yr, resolution was more common with a TSH of 4.5-6.9 mU/liter (46 vs. 10% with TSH 7-9.9 mU/liter and 7% with TSH ≥10 mU/liter; P < 0.001) and with TPOAb negativity (48 vs. 15% for positive; P < 0.001). Higher TSH and TPOAb positivity were independently associated with lower likelihood of reversion to euthyroidism (P < 0.05). TSH of 10 mU/liter or higher was independently associated with progression to overt hypothyroidism (P < 0.05). Transitions between euthyroidism and subclinical hypothyroidism were common between 2 and 4 yr. Age and sex did not affect transitions. CONCLUSIONS: Subclinical hypothyroidism persists for 4 yr in just over half of older individuals, with high rates of reversion to euthyroidism in individuals with lower TSH concentrations and TPOAb negativity. Future studies should examine the impact of transitions in thyroid status on clinical outcomes.
CONTEXT: Studies of long-term outcomes of subclinical hypothyroidism have assessed only baseline thyroid function, despite natural transitions to euthyroidism and overt hypothyroidism over time. OBJECTIVE: We provide estimates of persistence, resolution, and progression of subclinical hypothyroidism over 4 yr, stratified by baseline TSH, anti-thyroid peroxidase antibody (TPOAb) status, age, and sex. DESIGN, SETTING, AND PARTICIPANTS: Participants were 3996 U.S. individuals at least 65 yr old enrolled in the Cardiovascular Health Study. Subclinical hypothyroidism was detected at baseline in 459 individuals not taking thyroid medication. MAIN OUTCOME MEASURE: Thyroid function was evaluated at 2 and 4 yr and initiation of thyroid medication annually. Results were stratified by baseline TSH, TPOAb status, age, and sex. RESULTS: Persistence of subclinical hypothyroidism was 56% at 2 and 4 yr. At 2 yr, resolution was more common with a TSH of 4.5-6.9 mU/liter (46 vs. 10% with TSH 7-9.9 mU/liter and 7% with TSH ≥10 mU/liter; P < 0.001) and with TPOAb negativity (48 vs. 15% for positive; P < 0.001). Higher TSH and TPOAb positivity were independently associated with lower likelihood of reversion to euthyroidism (P < 0.05). TSH of 10 mU/liter or higher was independently associated with progression to overt hypothyroidism (P < 0.05). Transitions between euthyroidism and subclinical hypothyroidism were common between 2 and 4 yr. Age and sex did not affect transitions. CONCLUSIONS: Subclinical hypothyroidism persists for 4 yr in just over half of older individuals, with high rates of reversion to euthyroidism in individuals with lower TSH concentrations and TPOAb negativity. Future studies should examine the impact of transitions in thyroid status on clinical outcomes.
Authors: Hossein Gharib; R Michael Tuttle; H Jack Baskin; Lisa H Fish; Peter A Singer; Michael T McDermott Journal: J Clin Endocrinol Metab Date: 2005-01 Impact factor: 5.958
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Nicolas Rodondi; Anne B Newman; Eric Vittinghoff; Nathalie de Rekeneire; Suzanne Satterfield; Tamara B Harris; Douglas C Bauer Journal: Arch Intern Med Date: 2005-11-28
Authors: Jacobijn Gussekloo; Eric van Exel; Anton J M de Craen; Arend E Meinders; Marijke Frölich; Rudi G J Westendorp Journal: JAMA Date: 2004-12-01 Impact factor: 56.272
Authors: M P Vanderpump; W M Tunbridge; J M French; D Appleton; D Bates; F Clark; J Grimley Evans; D M Hasan; H Rodgers; F Tunbridge Journal: Clin Endocrinol (Oxf) Date: 1995-07 Impact factor: 3.478
Authors: Érique José F Peixoto de Miranda; Márcio Sommer Bittencourt; Alessandra C Goulart; Itamar S Santos; Silvia Maria de Oliveira Titan; Roberto Marini Ladeira; Sandhi Maria Barreto; Paulo A Lotufo; Isabela Judith Martins Benseñor Journal: Clin Exp Nephrol Date: 2017-03-27 Impact factor: 2.801
Authors: Lesley Roberts; Deborah McCahon; Oliver Johnson; M Sayeed Haque; James Parle; Fd Richard Hobbs Journal: Br J Gen Pract Date: 2018-08-28 Impact factor: 5.386
Authors: Vicky A LeGrys; Michele Jonsson Funk; Carol E Lorenz; Ayush Giri; Rebecca D Jackson; JoAnn E Manson; Robin Schectman; Todd L Edwards; Gerardo Heiss; Katherine E Hartmann Journal: J Clin Endocrinol Metab Date: 2013-03-28 Impact factor: 5.958